Breast Cancer

  • Avastin 2016 report

    Avastin 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 25 Pages The 5 Key Questions Addressed by this Report:...

  • Fareston 2016 report

    Fareston 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 26 Pages The 5 Key Questions Addressed by this Report:...

  • Faslodex 2016 report

    Faslodex 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 26 Pages The 5 Key Questions Addressed by this Report:...

  • Halaven 2016 report

    Halaven 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 24 Pages The 5 Key Questions Addressed by this Report:...

  • Herceptin 2016 report

    Herceptin 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 26 Pages The 5 Key Questions Addressed by this Report:...

  • Ibrance 2016 report

    Ibrance 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 21 Pages The 5 Key Questions Addressed by this Report:...

  • Ixempra 2016 report

    Ixempra 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 26 Pages The 5 Key Questions Addressed by this Report:...

  • Kadcyla 2016 report

    Kadcyla 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 24 Pages The 5 Key Questions Addressed by this Report:...

  • Perjeta 2016 report

    Perjeta 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 26 Pages The 5 Key Questions Addressed by this Report:...

  • Abraxane 2015 report

    Abraxane 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 27 Pages The 5 Key Questions Addressed by this...

  • Afinitor 2015 report

    Afinitor 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 31 Pages The 5 Key Questions Addressed by this...

  • Avastin 2015 report

    Avastin 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 26 Pages The 5 Key Questions Addressed by this...